Optimization of potassium management in patients with chronic kidney disease and type 2 diabetes on finerenone

References

• Perez-Gomez MV, Bartsch LA, Castillo-Rodriguez E, et al. Clarifying the concept of chronic kidney disease for non-nephrologists. Clin Kidney J. 2019;12(2):258–261. DOI:10.1093/ckj/sfz007
   PubMed Web of Science ®Google Scholar
• Chaudhuri A, Ghanim H, Arora P. Improving the residual risk of renal and cardiovascular outcomes in diabetic kidney disease: a review of pathophysiology, mechanisms, and evidence from recent trials. Diabetes ObesMetab. 2022r;24(3):365–376.
   PubMed Web of Science ®Google Scholar
• Wen CP, Chang CH, Tsai MK, et al. Diabetes with early kidney involvement may shorten life expectancy by 16 years. Kidney Int. 2017;92(2):388–396. DOI:10.1016/j.kint.2017.01.030
   PubMed Web of Science ®Google Scholar
• Lewis EJ, Hunsicker LG, Bain RP, et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med. 1993;329(20):1456–1462.
   PubMed Web of Science ®Google Scholar
• Brenner BM, Cooper ME, de Zeeuw D, et al. RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345(12):861–869. DOI:10.1056/NEJMoa011161
   PubMed Web of Science ®Google Scholar
• Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345(12):851–860. DOI:10.1056/NEJMoa011303
   PubMed Web of Science ®Google Scholar
• Perkovic V, Jardine MJ, Neal B, et al. CREDENCE trial investigators. canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295–2306. DOI:10.1056/NEJMoa1811744
   PubMed Web of Science ®Google Scholar
• Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al. DAPA-CKD trial committees and investigators. dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436–1446. DOI:10.1056/NEJMoa2024816
   PubMed Web of Science ®Google Scholar
• Bakris GL, Agarwal R, Anker SD, et al. FIDELIO-DKD investigators. effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med. 2020;383(23):2219–2229. DOI:10.1056/NEJMoa2025845
   PubMed Web of Science ®Google Scholar
• Pitt B, Filippatos G, Agarwal R, et al. FIGARO-DKD investigators. cardiovascular events with finerenone in kidney disease and type 2 diabetes. N Engl J Med. 2021;385(24):2252–2263. DOI:10.1056/NEJMoa2110956
   PubMed Web of Science ®Google Scholar
• Santoro A, Mandreoli M. Hyperkalemia as a limiting factor in the use of drugs that block the Renin Angiotensin Aldosterone System (RAAS). G Ital Nefrol. 2018;35(3).
   Google Scholar
• Valdivielso JM, Balafa O, Ekart R, et al. Hyperkalemia in chronic kidney disease in the new era of kidney protection therapies. Drugs. 2021;81(13):1467–1489. DOI:10.1007/s40265-021-01555-5
   PubMed Web of Science ®Google Scholar
• García-Maset R, Bover J, Segura de la Morena J, et al. Information and consensus document for the detection and management of chronic kidney disease. Nefrologia. Engl 2022;42(3):233–264. DOI:10.1016/j.nefroe.2022.07.003
   Google Scholar
• Goia-Nishide K, Coregliano-Ring L, Rangel ÉB. Hyperkalemia in Diabetes Mellitus Setting. Diseases. 2022 Mar 28;10(2):20. DOI:10.3390/diseases10020020
   PubMedGoogle Scholar
• Conway R, Creagh D, Byrne DG, et al. Serum potassium levels as an outcome determinant in acute medical admissions. Clin Med (Lond). 2015;15(3):239–243.
   PubMed Web of Science ®Google Scholar
• Palaka E, Grandy S, Darlington O, et al. Associations between serum potassium and adverse clinical outcomes: a systematic literature review. Int J Clin Pract. 2020;74(1):e13421.
   PubMed Web of Science ®Google Scholar
• Belmar Vega L, Galabia ER, da da Silva J B, et al. Epidemiology of hyperkalemia in chronic kidney disease. Nefrologia. 2019;39(3):277–286.
   PubMed Web of Science ®Google Scholar
• Loutradis C, Tolika P, Skodra A, et al. Prevalence of hyperkalemia in diabetic and non-diabetic patients with chronic kidney disease: a nested case-control study. Am J Nephrol. 2015;42(5):351–360.
   PubMed Web of Science ®Google Scholar
• Hunter RW, Bailey MA. Hyperkalemia: pathophysiology, risk factors and consequences. Nephrol Dial Transplant. 2019;34(Suppl 3):iii2–11.
   PubMedGoogle Scholar
• Kovesdy CP. Management of hyperkalaemia in chronic kidney disease. Nat Rev Nephrol. 2014 Nov;10(11):653–662. DOI:10.1038/nrneph.2014.168
   PubMed Web of Science ®Google Scholar
• Hollander-Rodriguez JC, JF C Jr. Hyperkalemia. Am Fam Physician. 2006;73(2):283–290.
   PubMed Web of Science ®Google Scholar
• Lehnhardt A, Kemper MJ. Pathogenesis, diagnosis and management of hyperkalemia. Pediatr Nephrol. 2011;26(3):377–384.
   PubMed Web of Science ®Google Scholar
• Wanner C, Fioretto P, Kovesdy CP, et al. Potassium management with finerenone: practical aspects. Endocrinol Diabetes Metab. 2022;5(6):e360.
   PubMedGoogle Scholar
• Rossignol P, Ruilope LM, Cupisti A, et al. Recurrent hyperkalaemia management and use of renin-angiotensin-aldosterone system inhibitors: a European multi-national targeted chart review. Clin Kidney J. 2020;13(4):714–719.
   PubMed Web of Science ®Google Scholar
• de Boer IH, Khunti K, Sadusky T, et al. Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: improving Global Outcomes (KDIGO). Kidney Int. 2022;102(5):974–989.
   PubMed Web of Science ®Google Scholar
• Epstein M. Aldosterone and Mineralocorticoid Receptor Signaling as Determinants of Cardiovascular and Renal Injury: from Hans Selye to the Present. Am J Nephrol. 2021;52(3):209–216.
   PubMed Web of Science ®Google Scholar
• Clase CM, Carrero JJ, Ellison DH, et al. Potassium homeostasis and management of dyskalemia in kidney diseases: conclusions from a Kidney Disease: improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2020;97(1):42–61.
   PubMed Web of Science ®Google Scholar
• Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease. Kidney Int. 2020;98(4S): S1–115. DOI:10.1016/j.kint.2020.06.019
   PubMedGoogle Scholar
• Rico-Fontalvo J, Álvarez-Estévez G, Sánchez-Polo V, et al. A Consensus of the Latin American Society of Nephrology and Hypertension about the role of mineralocorticoid receptor antagonists in chronic kidney disease. Nefro Latinoam. 2022;19:116–128.
   Google Scholar
• Palmer BF, Carrero JJ, Clegg DJ, et al. Clinical management of hyperkalemia. Mayo Clin Proc. 2021;96(3):744–762.
   PubMed Web of Science ®Google Scholar
• Chauveau P, Aparicio M, Bellizzi V, et al. Mediterranean diet as the diet of choice for patients with chronic kidney disease. Nephrol Dial Transplant. 2018;33(5):725–735.
   PubMed Web of Science ®Google Scholar
• Picard K, Griffiths M, Mager DR, et al. Handouts for low-potassium diets disproportionately restrict fruits and vegetables. J Ren Nutr. 2021;31(2):210–214.
   PubMed Web of Science ®Google Scholar
• Babich JS, Kalantar-Zadeh K, Joshi S. Taking the kale out of hyperkalemia: plant foods and serum potassium in patients with kidney disease. J Ren Nutr. 2022;32(6):641–649.
   PubMed Web of Science ®Google Scholar
• Agarwal R, Sinha AD, Cramer AE, et al. Chlorthalidone For hypertension in advanced chronic kidney disease. N Engl J Med. 2021;385(27):2507–2519.
   PubMed Web of Science ®Google Scholar
• Ishani A, Cushman WC, Leatherman SM, et al. Chlorthalidone vs. Hydrochlorothiazide for Hypertension-Cardiovascular Events. N Engl J Med. 2022;387(26):2401–2410.
   PubMed Web of Science ®Google Scholar
• Sumida K, Yamagata K, Kovesdy CP. Constipation in CKD. Kidney Int Rep. 2020;5:121–134.
   PubMed Web of Science ®Google Scholar
• Fernandez-Prado R, Villalvazo P, Avello A, et al. Sodium zirconium cyclosilicate and metabolic acidosis: potential mechanisms and clinical consequences. Biomedicine & Pharmacotherapy. 2023;158:114197.
   PubMed Web of Science ®Google Scholar
• Epstein M, Reaven NL, Funk SE, et al. Evaluation of the treatment gap between clinical guidelines and the utilization of renin-angiotensin-aldosterone system inhibitors. Am J Manag Care. 2015 Sep;21(11 Suppl):S212–20.
   PubMed Web of Science ®Google Scholar
• Bhandari S, Mehta S, Khwaja A, et al. STOP ACEi Trial Investigators. Renin-Angiotensin System Inhibition in Advanced Chronic Kidney Disease. N Engl J Med. 2022;387(22):2021–2032.
   PubMed Web of Science ®Google Scholar
• Herrington WG, Staplin N, Wanner C, et al. Empagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2023;388(2):117–127.
   PubMed Web of Science ®Google Scholar
• Rachmasari K, Montori VM. In type 2 diabetes, SGLT2 inhibitors reduced risk for serious hyperkalemia without increasing hypokalemia. Ann Intern Med. 2022;175(9): JC104. DOI:10.7326/J22-0063
   PubMed Web of Science ®Google Scholar
• Tsukamoto S, Morita R, Yamada T, et al. Cardiovascular and kidney outcomes of combination therapy with sodium-glucose cotransporter-2 inhibitors and mineralocorticoid receptor antagonists in patients with type 2 diabetes and chronic kidney disease: a systematic review and network meta-analysis. Diabet Res Clin Pract. 2022;194:110161.
   PubMed Web of Science ®Google Scholar
• Alicic RZ, Rooney MT, Tuttle KR. Diabetic kidney disease: challenges, progress, and possibilities. Clin J Am Soc Nephrol. 2017;12(12):2032–2045.
   PubMed Web of Science ®Google Scholar
• Epstein M. A podcast discussing aldosterone and mineralocorticoid receptor antagonists in 2021: a paradigm shift. Diabetes Ther. 2022;13(4):583–588.
   PubMed Web of Science ®Google Scholar
• Ortiz A. RICORS2040: the need for collaborative research in chronic kidney disease. Clin Kidney J. 2021;15(3):372–387.
   PubMed Web of Science ®Google Scholar
• Foreman KJ, Marquez N, Dolgert A, et al. Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016-40 for 195 countries and territories. Lancet. 2018;392(10159):2052–2090.
   PubMed Web of Science ®Google Scholar
• Boenink R, Astley ME, Huijben JA, et al. The ERA Registry Annual Report 2019: summary and age comparisons. Clin Kidney J. 2021;15(3):452–472.
   PubMed Web of Science ®Google Scholar
• Hundemer GL, Sood MM. Hyperkalemia with RAAS inhibition: mechanism, clinical significance, and management. Pharmacol Res. 2021;172:105835.
   PubMed Web of Science ®Google Scholar
• Górriz JL, González-Juanatey JR, Facila L, et al. Finerenone: towards a holistic therapeutic approach to patients with diabetic kidney disease. Nefrologia. 2022. DOI:10.1016/j.nefro.2022.09.002
   Google Scholar
• Agarwal R, Filippatos G, Pitt B, et al. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur Heart J. 2022;43(6):474–484.
   PubMed Web of Science ®Google Scholar
• Finerenone. Summary of product characteristics. Last accessed on Jan 2023. Available at: https://www.ema.europa.eu/en/documents/product-information/kerendia-epar-product-information_en.pdf
   Google Scholar
• Agarwal R, Kolkhof P, Bakris G, et al. Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine. Eur Heart J. 2021;42:152–161.
   PubMed Web of Science ®Google Scholar
• Kolkhof P, Jaisser F, Kim SY, et al. Steroidal and novel non-steroidal mineralocorticoid receptor antagonists in heart failure and cardiorenal diseases: comparison at bench and bedside. Handb Exp Pharmacol. 2017;243:271–305.
   PubMedGoogle Scholar
• Grune J, Beyhoff N, Smeir E, et al. Selective mineralocorticoid receptor cofactor modulation as molecular basis for finerenone’s antifibrotic activity. Hypertension. 2018;71(4):599–608.
   PubMed Web of Science ®Google Scholar
• Kawanami D, Takashi Y, Muta Y, et al. Mineralocorticoid receptor antagonists in diabetic kidney disease. Front Pharmacol. 2021;12:754239.
   PubMed Web of Science ®Google Scholar
• Wu Y, Lin H, Tao Y, et al. Network meta-analysis of mineralocorticoid receptor antagonists for diabetic kidney disease. Front Pharmacol. 2022;13:967317.
   PubMed Web of Science ®Google Scholar
• Amazit L, Le Billan F, Kolkhof P, et al. Finerenone impedes aldosterone-dependent nuclear import of the mineralocorticoid receptor and prevents genomic recruitment of steroid receptor coactivator-1. J Biol Chem. 2015;290(36):21876–21889.
   PubMed Web of Science ®Google Scholar
• Fagart J, Hillisch A, Huyet J, et al. A new mode of mineralocorticoid receptor antagonism by a potent and selective nonsteroidal molecule. J Biol Chem. 2010;285(39):29932–29940.
   PubMed Web of Science ®Google Scholar
• Pei H, Wang W, Zhao D, et al. The use of a novel non-steroidal mineralocorticoid receptor antagonist finerenone for the treatment of chronic heart failure: a systematic review and meta-analysis. Medicine (Baltimore). 2018;97(16):e0254.
   PubMed Web of Science ®Google Scholar
• Lindhardt M, Persson F, Currie G, et al. Proteomic prediction and Renin angiotensin aldosterone system Inhibition prevention of early diabetic nephRopathy in TYpe 2 diabetic patients with normoalbuminuria (PRIORITY): essential study design and rationale of a randomised clinical multicentre trial. BMJ Open. 2016;6(3):e010310.
   PubMed Web of Science ®Google Scholar
• Tofte N, Lindhardt M, Adamova K, et al. Characteristics of high- and low-risk individuals in the PRIORITY study: urinary proteomics and mineralocorticoid receptor antagonism for prevention of diabetic nephropathy in Type 2 diabetes. Diabet Med. 2018;35(10):1375–1382.
   PubMed Web of Science ®Google Scholar
• Tofte N, Lindhardt M, Adamova K, et al. Early detection of diabetic kidney disease by urinary proteomics and subsequent intervention with spironolactone to delay progression (PRIORITY): a prospective observational study and embedded randomised placebo-controlled trial. Lancet Diabetes Endocrinol. 2020;8(4):301–312.
   PubMed Web of Science ®Google Scholar
• An J, Niu F, Sim JJ. Cardiovascular and kidney outcomes of spironolactone or eplerenone in combination with ACEI/ARBs in patients with diabetic kidney disease. Pharmacotherapy. 2021;41(12):998–1008.
   PubMed Web of Science ®Google Scholar
• Pitt B, Kober L, Ponikowski P, et al. Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial. Eur Heart J. 2013;34(31):2453–2463.
   PubMed Web of Science ®Google Scholar
• Bakris GL, Agarwal R, Chan JC, et al. Effect of finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial. JAMA. 2015;314(9):884–894. DOI:10.1001/jama.2015.10081
   PubMed Web of Science ®Google Scholar
• Agarwal R, Rossignol P, Romero A, et al. Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet. 2019;394(10208):1540–1550.
   PubMed Web of Science ®Google Scholar
• Agarwal R, Pitt B, Palmer BF, et al. A comparative post hoc analysis of finerenone and spironolactone in resistant hypertension in moderate-to-advanced chronic kidney disease. Clin Kidney J. 2022;sfac234. DOI:10.1093/ckj/sfac234
   Web of Science ®Google Scholar
• Rossing P, Filippatos G, Agarwal R, et al. Finerenone in predominantly advanced CKD and type 2 diabetes with or without sodium-glucose cotransporter-2 inhibitor therapy. Kidney Int Rep. 2021 Oct 14;7(1):36–45. DOI:10.1016/j.ekir.2021.10.008
   PubMed Web of Science ®Google Scholar
• Zhang MZ, Bao W, Zheng QY, et al. Efficacy and safety of finerenone in chronic kidney disease: a systematic review and meta-analysis of randomized clinical trials. Front Pharmacol. 2022;13:819327.
   PubMedGoogle Scholar
• Lerma EV, Wilson DJ. Finerenone: a mineralocorticoid receptor antagonist for the treatment of chronic kidney disease associated with type 2 diabetes. Expert Rev ClinPharmacol. 2022;15(5):501–513.
   Google Scholar
• Marzolla V, Infante M, Armani A, et al. Efficacy and safety of finerenone for treatment of diabetic kidney disease: current knowledge and future perspective. Expert Opin Drug Saf. Epub ahead of print 2022 Sep 29. DOI:10.1080/14740338.2022.2130889
   Web of Science ®Google Scholar
• Agarwal R, Anker SD, Bakris G, et al. Investigating new treatment opportunities for patients with chronic kidney disease in type 2 diabetes: the role of finerenone. Nephrol Dial Transplant. 2022;37(6):1014–1023.
   PubMed Web of Science ®Google Scholar
• Goulooze SC, Snelder N, Seelmann A, et al. Finerenone dose-exposure-serum potassium response analysis of FIDELIO-DKD Phase III: the Role of Dosing, Titration, and Inclusion Criteria. Clin Pharmacokinet. 2022;61(3):451–462.
   PubMed Web of Science ®Google Scholar
• Agarwal R, Joseph A, Anker SD, et al. Hyperkalemia Risk with Finerenone: results from the FIDELIO-DKD Trial. J Am Soc Nephrol. 2022;33(1):225–237.
   PubMed Web of Science ®Google Scholar
• Chiu N, Aggarwal R, Bakris GL, et al. Generalizability of FIGARO-DKD and FIDELIO-DKD Trial Criteria to the US Population Eligible for Finerenone. J Am Heart Assoc. 2022:11(7):e025079. DOI:10.1161/JAHA.121.025079
   PubMed Web of Science ®Google Scholar
• Llisterri JL, Micó-Pérez RM, Velilla-Zancada S, et al. Prevalence of chronic kidney disease and associated factors in the Spanish population attended in primary care: results of the IBERICAN study. Med Clin. 2021;156(4):157–165.
   PubMed Web of Science ®Google Scholar
• Gorriz JL, D’Marco L, Pastor-González A, et al. Long-term mortality and trajectory of potassium measurements following an episode of acute severe hyperkalaemia. Nephrol Dial Transplant. 2022;37(3):522–530.
   PubMed Web of Science ®Google Scholar
• Shaikh A, Ray J, Campbell KN. Role of finerenone in the treatment of diabetic kidney disease: patient selection and clinical perspectives. TherClin Risk Manag. 2022;18:753–760.
   PubMed Web of Science ®Google Scholar
• Leon SJ, Tangri N. Balancing hyperkalemia risks with clinical benefits of renin-angiotensin-aldosterone inhibitors/mineralocorticoid receptor antagonists blockade: it’s apples and oranges. Kidney360. 2022;3(8):1442–1444.
   PubMedGoogle Scholar
• Lerma E, White WB, Bakris G. Effectiveness of nonsteroidal mineralocorticoid receptor antagonists in patients with diabetic kidney disease. Postgrad Med. 2022;1–10. DOI:10.1080/00325481.2022.2060598
   Web of Science ®Google Scholar
• Draznin B, Aroda VR, Bakris G, et al. 11. chronic kidney disease and risk management: standards of medical care in diabetes-2022. Diabetes Care. 2022;45(Suppl 1):S175–184.
   PubMedGoogle Scholar
• ElSayed NA, Aleppo G, Aroda VR, et al. 11. chronic kidney disease and risk management: standards of care in diabetes-2023. Diabetes Care. 2023 Jan 1;46(Supplement_1):S191–202. DOI:10.2337/dc23-S011
   PubMedGoogle Scholar
• Raj R. Finerenone: a new mineralocorticoid receptor antagonist to beat chronic kidney disease. Cur rOpin Nephrol Hypertens. 2022;31(3):265–271.
   PubMed Web of Science ®Google Scholar
• Kolkhof P, Hartmann E, Freyberger A, et al. Effects of finerenone combined with empagliflozin in a model of hypertension-induced end-organ damage. Am J Nephrol. 2021;52(8):642–652.
   PubMed Web of Science ®Google Scholar
• Neuen BL, Jardine MJ. SGLT2 inhibitors and finerenone: one or the other or both? Nephrol Dial Transplant. 2022 Jun 23;37(7):1209–1211. DOI:10.1093/ndt/gfac046
   PubMed Web of Science ®Google Scholar
• Neuen BL, Oshima M, Perkovic V, et al. Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trial. Eur Heart J. 2021;42:4891–4901.
   PubMed Web of Science ®Google Scholar
• Singh AK, Singh R. Renin-angiotensin system blockers-SGLT-2 inhibitors-mineralocorticoid receptor antagonists in diabetic kidney disease: a tale of the past two decades! World J Diabetes. 2022;13(7):471–481.
   PubMed Web of Science ®Google Scholar
• Provenzano M, Puchades MJ, Garofalo C, et al. Albuminuria-lowering effect of dapagliflozin, eplerenone, and their combination in patients with chronic kidney disease: a randomized crossover clinical trial. J Am Soc Nephrol. 2022;33(8):1569–1580.
   PubMed Web of Science ®Google Scholar
• Green JB, Mottl AK, Bakris G, et al. Design of the COmbinatioN effect of Finerenone and EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using an UACR Endpoint study (CONFIDENCE). Nephrol Dial Transplant. 2022 Jun 14. gfac198. 10.1093/ndt/gfac198. Epub ahead of print
   Web of Science ®Google Scholar
• Agarwal R, Anker SD, Filippatos G, et al. Effects of canagliflozin versus finerenone on cardiorenal outcomes: exploratory post hoc analyses from FIDELIO-DKD compared to reported CREDENCE results. Nephrol Dial Transplant. 2022;37(7):1261–1269.
   PubMed Web of Science ®Google Scholar
• Rebelos E, Tentolouris N. Complementary actions of finerenone and SGLT2-i on renal outcomes?: an urgent need for more information. Nephrology (Carlton). 2022;27(12):915–916.
   PubMed Web of Science ®Google Scholar
• Nuffield Department of Population Health Renal Studies Group. SGLT2 inhibitor meta-analysis cardio-renal trialists’ consortium. impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. Lancet. 2022;400(10365): 1788–1801. DOI:10.1016/S0140-6736(22)02074-8
   PubMed Web of Science ®Google Scholar
• Bosch C, Carriazo S, Soler MJ, et al. Tirzepatide and prevention of chronic kidney disease. Clin Kidney J. 2022;sfac274. DOI:10.1093/ckj/sfac274
   Google Scholar
• Jin T, Fu X, Liu M, et al. Finerenone attenuates myocardial apoptosis, metabolic disturbance and myocardial fibrosis in type 2 diabetes mellitus. Diabetol Metab Syndr. 2023;15(1):87.
   PubMed Web of Science ®Google Scholar
• Lv R, Xu L, Che L, et al. Cardiovascular-renal protective effect and molecular mechanism of finerenone in type 2 diabetic mellitus. Front Endocrinol. 2023;14:1125693.
   PubMed Web of Science ®Google Scholar
• González-Juanatey JR, Górriz JL, Ortiz A, et al. Cardiorenal benefits of finerenone: protecting kidney and heart. Ann Med. 2023;55(1):502–513.
   PubMed Web of Science ®Google Scholar